Andrew D. Zelenetz, MD, PhD

The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space.

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options.

Andrew Zelenetz, MD, PhD, discusses the dual strategy of using the duration of benefit metric and re-biopsy to navigate complex sequencing decisions in targeted lymphoma therapy.

The NCCN guidance transitioned from a specific focus on rituximab to a broad, future-proof policy covering all FDA-approved biosimilars, which simplifies treatment decisions and promotes patient access.

Andrew Zelenetz, MD, PhD, discusses how patient characteristics and disease history play into treatment strategy for follicular lymphoma.

Andrew Zelenetz, MD, PhD, addresses the potential for CD19 antigen loss, the lack of robust data, and the influence of newer, highly efficacious combination therapies on the sequencing decisions in follicular lymphoma.

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and longer-term data are needed to definitively determine its effectiveness.

Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial.

While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent.

Current NCCN Guidelines recommend molecular testing for patients with follicular lymphoma, which has improved diagnostic accuracy and can assist in selecting the appropriate treatment in certain cases.